American Association for the Advancement of Science, Science Translational Medicine, 446(10), 2018
DOI: 10.1126/scitranslmed.aao2301
Full text: Unavailable
K-RAS –mutated lung adenocarcinomas depend on ERBB signaling, and pan-ERBB inhibitors impair K-RAS–driven lung tumorigenesis.